Pseudomyxoma Peritonei Surgery and Treatment
We're "veterans" of pseudomyxoma peritonei surgery and we'll support you!
How is PMP treated?
What are the treatment options for Pseudomyxoma Peritonei?
Is surgery required for Pseudomyxoma Peritonei treatment?
What treatment therapy is standard care for Pseudomyxoma Peritonei syndrome treatment?
What are CRS surgery and HIPEC therapy?
Are you or a loved one preparing for surgery for the treatment of Pseudomyxoma Peritonei syndrome?
The PMP Pals' Network provides a wide variety of services to assist you in preparing for, and recuperating from, surgery as quickly as possible!
Our 2012 Preparing for Surgery Handbook and Newsletters provide step by step instructions to assist you with preparing for and recuperating from treatment.
Our Pal Mentors will personally communicate with you via telephone, email, personal visits, SKYPE or web cam to help you, or your loved one prepare for surgery and/or HIPEC. We will share helpful resources and positive information to guide you through your recuperation!
We are here to assist you in returning to your full and active life, as soon as possible!
View photos and profiles of successful surgery survivors!
Pseudomyxoma Peritonei Surgery, HIPEC and Chemotherapy overview
Your surgical oncologist will explain and review all treatment options for Pseudomyxoma Peritonei. Your treatment plan will depend on your overall health, the type of tumor (pathology), the quantity (mass) size and location of the tumor, and whether the cancer has metastasized.
Treatment for the Pseudomyxoma Peritonei syndrome generally includes CRS or cytoreductive surgery with or without systemic chemotherapy and HIPEC.
The purpose of debulking surgery is to remove as much tumor as possible. Debulking surgery often includes the removal of the omentum and the right colon. Additionally, for women, debulking will likely include a hysterectomy, if this was not perfomed previously. Adhesions become more troublesome with any additional debulking surgeries.
Cytoreductive surgery is a detailed, lengthy procedure often requiring ten or more hours.
Tumors are removed and destroyed using a variety of surgical techniques including argon beam coagulator, electro-evaporation, laser, and ultrasonic dissection.
CRS (cytoreductive surgery) consists of the removal of as much mucin and visible tumor as possible, from the abdominal cavity. CRS surgery, refers to the removal of all visible tumors present throughout the peritoneal cavity. Cytoreductive Surgery includes thorough removal or destruction of all visible tumors throughout the surfaces of the peritoneum. Surgery may include the removal or resection of segments of small and large bowel, gall bladder, liver, omentum, ovaries, pancreas, spleen, stomach and uterus, and may require removing the lining of the peritoneum.
Hemicolectomy is a surgical procedure involving the removal of a portion of the colon next to the appendix. This procedure may also include the removal of nearby blood vessels and lymph nodes at the same time.
Peritonectomy refers to stripping the parietal peritoneum and resecting structures at the sites that contain adenomucinosis. A combination of surgical techniques are utilized including organ resection, when necessary and tumor destruction via electro-evaporation and argon beam coagulation.
CRS surgery for Appendix Cancer and Pseudomyxoma Peritonei may include the following:
Removal of the omentum, spleen and gall bladder,
Right hemicolectomy, colectomy, removal of the rectum and sigmoid,
Stripping tumor from the surface of the liver,
Resection of the pancreas,
Gastrectomy (partial or total removal of the stomach)
Stripping the peritoneum from left and right hemidiaphragm;
Pelvic peritonectomy,
Ileostomy,colostomy or urostomy
HIPEC may be included at the conclusion of the cytoreductive surgery for the treatment of pseudomyxoma peritonei and appendix cancer if substantial tumor debulking is accomplished through CRS. HIPEC may be administered when complete removal of visible tumor (or debulking) is achieved through cytoreductive surgery; it involves perfusion of the peritoneal cavity with chemotherapy heated to approximately 40 degrees Celsius.
HIPEC is administered with the infusion of heated chemotherapy during the last 90 minutes of the CRS procedure. Through HIPEC the surgeon(s) intend to destroy any residual tumor cells that may not have been surgically removed during the actual CRS surgery process.
Although this procedure may initially sound drastic to the newly diagnosed patient, rarely is resection and/or removal of all of these organs is required. Each patient's case is unique and most patients live productive and healthy lives following surgery!
Learn about HIPEC
Learn how to prepare for surgery
Order the PMP Pals' Network Handbook: Preparing for Surgery.*
Slideshow "Getting Ready for Surgery" provides generic surgery information
Presented by WB MD, August 2010
Ostomies
Request a Pal Mentor to help you prepare for and recuperate from surgery!
Our Pal Mentors are "veterans" of surgery with Drs. Ahrendt, Bartlett, Esquivel, Goodman, Holtzman,Levine, Loggie, Lowy, Mansfield, Moran, Morris, Pingpank, Temple, Sardi, Shen, Stewart, Sugarbaker, Selby and Zeh!
Learn more about systemic Chemotherapy
CRS (Cytoreductive Surgery) in conjunction with HIPEC: Articles and Abstracts
This week's featured articles:
Upfront Compared to Delayed Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Is Associated With Considerably Lower Perioperative Morbidity and Recurrence Rate.Chua TC, Liauw W, Zhao J, Morris DL.
*UNSW Department of Surgery, St George Hospital, Kogarah, Sydney, Australia. †Department of Medical Oncology, Cancer Care Centre, St George Hospital, Kogarah, Sydney, Australia.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) is a recognized management strategy for pseudomyxoma peritonei. We seek to evaluate the outcomes of patients treated upfront with CRS PIC compared to patients undergoing delayed CRS PIC as salvage or treatment for recurrences after initial debulking surgery.
METHODS: Retrospective analysis of patients with low-grade pseudomyxoma peritonei treated within our institution were stratified according to upfront versus delayed CRS PIC after intial debulking surgery. Survival was analyzed using the Kaplan-Meier method and compared using the log-rank test.
RESULTS: Of 83 patients treated, 35 patients (42%) underwent upfront and 48 patients (58%) underwent delayed CRS PIC. The peritoneal cancer index (P = 0.048), amount of blood transfusion intraoperatively (P = 0.003) and duration of operation (P = 0.007) was lesser in the upfront compared to delayed group. Upfront treatment confers 5-year recurrence-free survival benefit (77% vs 37%; P = 0.011) and 10-year overall survival benefit (67% vs 35%; P = 0.054) over delayed treatment.
CONCLUSION: Upfront CRS PIC seems to confer beneficial perioperative outcomes and lower recurrence rates over delayed CRS PIC. Early referral to centralized treatment centers would seem to be a reasonable strategy to improve outcomes.
Source: Annals of Surgical Oncology, Jan 13, 2011
Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients with Limited Peritoneal Surface Malignancies: Feasibility, Morbidity and Outcome in an Early Experience.
Laparoscopic CRS and HIPEC in Patients with Limited PSMs
Source: Esquivel J, Averbach A, Chua TC St. Agnes Hospital, Baltimore, Maryland.
Ann Surg. 2011 Jan 6. [Epub ahead of print]
Abstract
INTRODUCTION: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are being widely used in the treatment of patients with peritoneal surface malignancies. The open procedure has been associated with high grade III and IV morbidity and prolonged hospitalization.
METHODS: Patients with peritoneal surface malignancies and no gross evidence of carcinomatosis on the computed tomographic scan were enrolled to undergo laparoscopic CRS and HIPEC. We aimed to assess the feasibility, safety, and outcome of this procedure. Postoperative complications were reported according to the National Cancer Institute Common Toxicity Criteria.
RESULTS: From October 2008 to January 2010, 14 patients were enrolled into the protocol. Amongst these 14 patients, one patient was found with extensive carcinomatosis at the time of laparoscopy and had no surgical procedure. Thirteen patients had a complete cytoreduction and HIPEC, 10 (77%) laparoscopically and 3 (23%) were converted to an open procedure. There was one grade 3 morbidity (10%) and one patient (10%) in the laparoscopy group experienced a grade 4 complication, needing a reoperation for an internal hernia. Mean length of hospital stay was 6 days for those completed laparoscopically, 8 days for those converted to an open procedure and 8 days for a matched cohort of patients with an upfront open procedure.
CONCLUSIONS: This initial investigative stage demonstrates the feasibility and safety of cytoreductive surgery and HIPEC via the laparoscopic route in selected patients with low-tumor volume and no small bowel involvement mainly from appendiceal malignancies. Longer follow-up and additional studies are required to evaluate its long-term efficacy.
PMID: 21217512 [PubMed - as supplied by publisher] January 2011
Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Terence C. Chua, BScMed (Hons), MBBS 1, Kelly Thornbury, BMed 1, Akshat Saxena, BMedSc 1, Winston Liauw, MBBS, M Med Sci 2, Derek Glenn, MBBS 3, Jing Zhao, MD 1, David L. Morris, MD, PhD 1 *
1Department of Surgery, University of New South Wales, St George Hospital, Sydney, Australia
2Cancer Care Center, St George Hospital, Sydney, Australia
3Department of Radiology, St George Hospital, Sydney, Australia
Source: AMC Feb 2010
Treatment of Peritoneal Malignancies, including Pseudomyxoma Peritonei with CRS and HIPEC
CONCLUSION: It is important to recognize the role of and indications for CRS and HIPEC. Biologic factors of the disease and completeness of resection are important prognostic factors. Cytoreductive surgery, combined with intraperitoneal chemotherapy, can improve survival in selected patients with peritoneal-based malignancies.
Source:Department of Surgical Oncology, National Cancer Centre of Singapore, Singapore 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
12 Year Study of CRS and HIPEC for Pseudomyxoma Peritonei Treatment
Source: In Vivo, 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
HIPEC: Complexity
Source: Dr David L Bartlett,Journal of Surgical Oncology
Twelve year study of Pseudomyxoma Peritonei Treatment with CRS and HIPEC
Source: San Giuseppe Hospital, June 2009
Pleural Pseudomyxoma Peritonei Treatment with Thoracic CRS and HIPEC
Source: University of New South Wales, Australia, 2009
Pseudomyxoma Peritonei Treatment with CRS and HIPEC
Source: Universite de Montreal, Canada, 2009
HIPEC Treatment provided at St Agnes
Source: Dr Jesus Esquivel
Pseudomyxoma Peritonei Treatment with Cytoreductive Surgery and HIPEC
Source: British Journal of Surgery, Aug 2008
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Pseudomyxoma Peritonei Treatment with Chemo Hyperthermic Perfusion(CHPP)
Source: Pub Med 2009
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annuals of Surgical Oncology, 2008
International Consensus of PSMG for CRS and HIPEC
Source: Springerlink, Oct 2006
Recommended Reading:
Questions Patients Need to Ask by Dr David Shulkin
Source: Amazon.com, Barnes and Noble, Ebay
Read ratings for physicians across the USA
Alpha Index of Surgery Articles by "PMP" Cancer Specialists
International listing of research articles and abstracts
See our SURGEONS & SPECIALISTS link for additional information about these physicians.
We provide the following abstracts and articles, published by, and/or written about the world's most experienced specialists in the treatment and research of Pseudomyxoma Peritonei, and Appendix Cancer. The full titles of some abstracts have been abbreviated due to space limitations.
Articles by Dr SA Ahrendt, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Fernando Arias, Colombia
Sleeve Gastrectomy
Source: Fundacion Santa Fe de Bogota
Abstracts by Dr Mario Baratti, Italy
Pseudomyxoma PeritoneiBiological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
Articles by Dr David L Bartlett, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Anuals of Surgical Oncology, 2008
HIPEC: The Complexity of Clinical Trials
Source: Dr David L Bartlett, UPMC, Society of Surgical Oncology 2008
Dr David L Bartlett, Dr James Pingpank, Dr Steven Ahrendt
Source: Koch Cancer Treatment Center, UPMC
Profile for Dr David L Bartlett
Source: UPMC
Dr David L Bartlett: Koch Cancer Center
Source: UPMC
Dr David L Bartlett: Treatment of Liver Cancer
Source: UPMC Koch Cancer Center
Articles by Dr Jean Bereder, France
Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie. Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Wim Ceelen, Belgium
Dr Wim P Ceelen treats Pseudomyxoma Peritonei with HIPEC www.surgery.ugent.be
Articles by Dr Marcello Deraco, Italy
Pseudomyxoma PeritoneiBiological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
HIPEC Treatment: Dott. Marcello Deraco: Pseudomyxoma Peritonei and Appendix Cancer
Source: Dott. Marcello Deraco
Articles by Dr D Elias, France
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Jesus Esquivel, USA
Learning Curve for CRS and HIPEC
Source: Journal of Surgical Oncology, August 2009
Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009
HIPEC Treatment available at St Agnes Hospital
Source: Dr Jesus Esquivel
Pros and Cons of HIPEC: Dr Jesus Esquivel
Source: Oncology Times, Jan 2007
Physician Profile for Dr Jesus Esquivel
Source: St Agnes Hospital
Dr Jesus Esquivel:St Agnes Hospital
Source: St Agnes Hospital
Articles by Dr Jan Franko, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Click here to read Dr Jan Franko's profile
Source: Mercy Medical Center
Articles by Dr Gilly, France
Study of 300+ Patients Treated with CRS and PIC :
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients Source: Journal of Clinical Oncology 2008
Articles by Dr Joachim Jahne, Germany
CRS:Stategies to Reduce Post Op Morbidity and Complications
Source: Dr Joachim Jahne, April 2009
Articles by Dr Santiago Gonzalez-Moreno, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr Martin Goodman, USA
Dr Martin Goodman at Tufts University provides HIPEC
Source: Tufts University, Boston
Articles by Dr Matthew Holtzman, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr Laura Lambert, USA
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Articles by Dr Edward Levine, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
“Appendiceal Carcinoma with Peritoneal Dissemination: Outcomes for the Best of the Best.”
Source: Annals of Surgical Oncology,2007, Dr Edward Levine, WFU
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
DPAM and HIPEC Treatment
Source: Wake Forest University
Articles by Dr Brian W Loggie, USA
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Cox II expression in patients with Pseudomyxoma Peritonei and Disseminated Peritoneal Adenomucinosis
Source: Dr Brian Loggie
Articles referring to Dr Brian Loggie's patients
Source: PMP Pals' Network
Articles by Dr Andrew Lowy, USA
Minimally Invasive Laparoscopic Treatment of Pseudomyxoma Peritonei
Source: UCSD, Dr Andrew Lowy, 2009
Dr Andrew Lowy:Moores Cancer Center
Source: UCSD
Treatment of Pancreatic Cancer
Source: Dr Andrew Lowy UCSD
Articles by Dr Paul Mansfield, USA
Profile for Dr Paul Mansfield
Source: MD Anderson
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Paul Mansfield, ASCO 2008
CRS and Perioperative Intraperitoneal Chemotherapy for Colorectal Carcinomatosis:
Source: Annals of Surgical Oncology. 2007, Lambert, Laura A. and Paul F. Mansfield.
See: http://www.annalssurgicaloncology.org/cgi/content/full/14/11/3037
Laparoscopic Staging for Gastric Cancer
Source: Dr Paul Mansfield, MDACC, Annals of Surgical Oncology, 2001
Laparoscopy for Surgical Oncology
Source: MDACC
Articles by Dr Brendan J Moran, United Kingdom
CRS and HIPEC for the Treatment of Patients age 30-77 years
Source: North Hampshire Hospital, Basingstoke UK, 2007
Articles by Prof David L Morris, Australia
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Source: David L. Morris, MD, PhD 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris, 2009
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, NSW, AU
Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience.
This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
In vivo model for Pseudomyxoma Peritonei research
Source: Prof David L Morris, Sydney Australia, 2009
Articles by Dr Stefaan Mulier, Belgium
Dr Stefaan Mulier provides HIPEC treatment for Pseudomyxoma Peritonei and Peritoneal Carcinomatosis
Source: Leopold Park Clinic in Brussels
Articles by Dr Herwart Mueller, German
CRS for Senior Patients
Source: Dr Herwart Mueller, Germany
Articles by Dr Garrett M Nash USA
Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY
Articles by Dr Haydee Ojeda-Fournier, USA
Diagnostic Imaging of Pancreatic Cancer
Source: Dr Haydee Ojeda-Fournier, UCSD
Articles by Dr Gloria Ortega-Perez, Spain
Patient Selection for CRS and HIPEC
Source: Journal of Surgical Oncology 2009
Articles by Dr James Pingpank, USA
Peritoneal Carcinomatois Clinical Trials Study
Source: NIH, Dr James Pingpank, Feb 2009
Articles by Prof Pompiliu Piso, Germany
Peritoneal Carcinomatosis Treatment (Study) with Tumor Honing Peptides
Source: Dept of Radiology, Germany 2009
Peritoneal Carcinomatosis Prognosis following treatment with surgery and HIPEC
Source: Prof P Piso, 2009
CRS and HIPEC for the Treatment of Peritoneal Carcinomatosis
Source: Prof Pompiliu Piso, 3rd Annual Symposium, 2008
HIPEC Study with laboratory rats
Source: Deutscher Krebskongress, 2004
Articles by Dr B Ronnett, USA
CRS and HIPEC for the Treatment of Peritoneal Dissemination of Appendiceal and Colorectal Neoplasms
Source: Dr Edward Levine, ASCO 2008
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Articles by Dr Armando Sardi, USA
CRS and HIPEC offer longterm survival for Peritoneal Carcinomatosis of disseminated Appendiceal tumor origin
Source: Dr Armando Sardi, Mercy Med Center, Journal of American College of Surgeons, Sept 2009
Published abstracts by Dr Armando Sardi
Source: Mercy Medical Center
Steps to Prepare for SurgerySource: Mercy Medical Center
Curriculum Vitae for Dr Armando Sardi
Source: Mercy Medical Center
Profile for Dr Armando Sardi
Source: Mercy Medical Center
Articles by Dr Perry Shen, USA
Dr Perry Shen at WFU provides HIPEC
Source: Wake Forest University
Articles by Dr Paul H Sugarbaker, USA
Mesenteric Cyst resulting in Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2010
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Epithelial appendiceal neoplasms (abstract with availability to purchase article in full)
Source: The Cancer Journal, 2009
Epithelial appendiceal neoplasms: report reviews 900 cases treated at the Washington Hospital Center
Source: Dr Paul H Sugarbaker, Cancer Journal, May 2009
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Management of mucinous urachal neoplasm presenting as Pseudomyxoma Peritonei
Source: Dr Paul H Sugarbaker, 2008
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Cytoreductive Surgery (includes graphic illustrations) Source: Dr Paul H Sugarbaker
Indications for use of CRS and HIPEC
Source: Dr Paul H Sugarbaker
Appendix Cancer Prognosis
Source: Dr Paul H Sugarbaker, Washington Hospital Center
Prognostic indicators for Peritoneal Carcinomatosis originating with gastrointestinal adenocarcinoma
Source: Dr Paul H Sugarbaker, 2005
Atlas of Appendix Cancer(includes graphic illustrations)
Source: Dr Paul H Sugarbaker
Articles referring to Dr Paul Sugarbaker and his patients
Source: PMP Pals' Network
Articles by Dr V J Verwaal,Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
Cytoreduction and HIPEC Treatment for Appendix Cancer and Pseudomyxoma Peritonei (pdf)
Source: Netherlands Cancer Institute, Prof VJ Verwaal, 2006
Articles by Dr Tristan Yan, Australia
Cost effectiveness of treatment with CRS and HIPEC
Source: Dr David L Morris, Dr Tristan Yan, Dec 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
Assessment of risk factors following CRS and chemotherapy
Source: Dr David L Morris, Dr Tristan Yan, 2009
Failure Analysis of Recurrent Disease Following CRS and IPC for Colorectal Cancer with Peritoneal Carcinomatosis
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, 2007
Treatment of Peritoneal Surface Malignancy
Source: Dr Paul H Sugarbaker, Dr Tristan Yan, Journal of Transistional Medicine, 2006
Articles by Dr H Zeh, USA
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis in Colorectal Cancer Patient with Liver Metastasis: Study of 57 Patients
Source: Journal of Clinical Oncology 2008
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgical Oncology, 2008
CRS and HIPEC for Treatment of Colorectal Carcinomatosis
Source: Annals of Surgial Oncology, Nov 2008
Articles by Dr F Zoetmulder, Holland
Population Based Study of Appendiceal Neoplasms and Pseudomyxoma Peritonei
Source: ESJO, 2008
Cytoreductive Surgery in conjunction with HIPEC
CRS (Cytoreductive Surgery) in conjunction with HIPEC:
Articles and Abstracts
Study of 300+ Patients Treated with CRS and PIC
Abstract of a study of 300+ Pseudomyxoma Peritonei patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Describes "gold standard " of treatment.
Source: Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; the Association Française de Chirurgie.
Department of Oncologic Surgery, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif Cédex, France March 2010
Radiofrequency Ablation for Treatment of Unresectable Colorectal Pulmonary Metastes
Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases. Radiofrequency ablation for colorectal pulmonary metastases represents a step forward towards a nonsurgical option of combining systemic and local treatment for metastatic disease and is a safe treatment with a low risk profile.
Terence C. Chua, BScMed (Hons), MBBS 1, Kelly Thornbury, BMed 1, Akshat Saxena, BMedSc 1, Winston Liauw, MBBS, M Med Sci 2, Derek Glenn, MBBS 3, Jing Zhao, MD 1, David L. Morris, MD, PhD 1 *
1Department of Surgery, University of New South Wales, St George Hospital, Sydney, Australia
2Cancer Care Center, St George Hospital, Sydney, Australia
3Department of Radiology, St George Hospital, Sydney, Australia
Source: AMC Feb 2010
Treatment of Peritoneal Malignancies, including Pseudomyxoma Peritonei with CRS and HIPEC
CONCLUSION: It is important to recognize the role of and indications for CRS and HIPEC. Biologic factors of the disease and completeness of resection are important prognostic factors. Cytoreductive surgery, combined with intraperitoneal chemotherapy, can improve survival in selected patients with peritoneal-based malignancies.
Source:Department of Surgical Oncology, National Cancer Centre of Singapore, Singapore 2010
Study of 523 Colorectal Peritoneal Carcinomatosis Cases: CRS and IPC
Source: Journal of Clinical Oncology,2010
12 Year Study of CRS and HIPEC for Pseudomyxoma Peritonei Treatment
Source: In Vivo, 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
HIPEC: Complexity
Source: Dr David L Bartlett,Journal of Surgical Oncology
Twelve year study of Pseudomyxoma Peritonei Treatment with CRS and HIPEC
Source: San Giuseppe Hospital, June 2009
Pleural Pseudomyxoma Peritonei Treatment with Thoracic CRS and HIPEC
Source: University of New South Wales, Australia, 2009
Pseudomyxoma Peritonei Treatment with CRS and HIPEC
Source: Universite de Montreal, Canada, 2009
HIPEC Treatment provided at St Agnes
Source: Dr Jesus Esquivel
Pseudomyxoma Peritonei Treatment with Cytoreductive Surgery and HIPEC
Source: British Journal of Surgery, Aug 2008
Tailgut Cyst: An Unusual Case of Pseudomyxoma Peritonei
Source: Tumori, Dr Paul H Sugarbaker, 2009
Pseudomyxoma Peritonei Treatment with Chemo Hyperthermic Perfusion(CHPP)
Source: Pub Med 2009
CRS and HIPEC for Treatment of Peritoneal Carcinomatosis
Source: Annuals of Surgical Oncology, 2008
International Consensus of PSMG for CRS and HIPEC
Source: Springerlink, Oct 2006
Laparoscopy; Minimally Invasive Staging and Surgery
Laparoscopy surgery includes the use of a thin, narrow, tube shaped instrument inserted into the abdominal wall. Laparoscopy may be used as a diagnostic tool, and has become a surgical option for specific patients, providing a less invasive (and less expensive) alternative to more extensive surgery. Recuperation from laparoscopy requires less hospitalization due to a faster recovery period, with less trauma and post op pain.
The following articles and abstracts pertaining to mesothelioma, pseudomyxoma peritonei, gastric, liver, ovarian and pancreatic cancer are posted for your reference.
Laparoscopy for Oncological Surgery (this article provides a detailed explanation for patients)
Source: MDAnderson, Houston TX
Laparoscopic Mucin Removal of Pseudomyxoma Peritonei
Source: Dept of OB GYN, Kinko Univ, Osaka Japan, 2009
Minimally Invasive Laparoscopic Surgery
Source: Mercy Medical Center
Minimally Invasive Laparoscopic Surgery, Liver, Pancreas
Source: UCSD, Dr Andrew Lowy, 2009
Laparoscopic CRS and HIPEC Treatment for Peritoneal Mesothelioma
Source: Dr Jesus Esquivel, 2009
Laparoscopic Surgery for the Treatment of Peritoneal Surface Malignancies including Pseudomyxoma Peritonei
Source: Memorial Sloan Kettering, NY
Laparoscopic Surgery for the Treatment of Liver Cancer, Pancreas Cancer
Source: University of Southern California
Laparoscopic Staging for Gastric Cancer
Source: Dr Paul Mansfield, MDACC, Annals of Surgical Oncology, 2001
Laparoscopic Colon Resection
Source: UPMC Koch Cancer Treatment Center
Laparoscopic Surgery for Liver Cancer
Source: Dr David L Bartlett UPMC Koch Cancer Center
Laparoscopic Surgery for Whipple Procedure, Pancreatic
Source: USC Norris Cancer Center
Laparoscopic Surgery, Gastric and Esophageal Cancers
Source: Dr Charles Filipi, Creighton University
Laparoscopic restoration of the colon continuity after Hartmann procedure
Source: Pub Med 2009
Laparoscopic Management of Ovarian Cyst
Source: Springerlink:2008
Laparoscopic Management of Pseudomyxoma Peritonei
Source: Cleveland Clinic 1999
Cecum Preserving Right Hemicolectomy
Source: Clinical Robotics, 2010
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice. Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.Copyright 2012 by PMP Pals' Network.
The PMP Pals' Network updates our website 363 days per year with a wide variety of new information to keep you informed about maintaining optimal health!
Whether you seek information about research studies, health insurance, personal mentoring, diet and exercise, new treatment options, and so much more, the PMP Pals' Network is your "go to" place for information!
Last update 02.24.12
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.Copyright 2012 by PMP Pals' Network.
The PMP Pals' Network updates our website 363 days per year with a wide variety of new information to keep you informed about maintaining optimal health!
Whether you seek information about research studies, health insurance, personal mentoring, diet and exercise, new treatment options, and so much more, the PMP Pals' Network is your "go to" place for information!
Last update 02.24.12
